Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325058 | 0.83 | GAA (0.37) | ALDH1A1KDM4EGAACCR2SPHK2 | |
| SCHEMBL4331350 | 0.81 | ALDH1A1 (0.33) | ALDH1A1KDM4ECNR1CNR2 | |
| SCHEMBL4326601 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KDM4EGAACNR1CNR2 | |
| SCHEMBL4326605 | 0.80 | ALDH1A1 (0.38) | ALDH1A1KDM4EGAACNR1CNR2 | |
| SCHEMBL4331963 | 0.79 | PSEN1 (0.36) | ALDH1A1HPGDCNR1CNR2 | |
| SCHEMBL4322304 | 0.78 | POLB (0.36) | ALDH1A1GAA | |
| SCHEMBL4330375 | 0.76 | GAA (0.40) | ALDH1A1GAACCR2SPHK2SPHK1 | |
| SCHEMBL4330378 | 0.76 | GAA (0.40) | ALDH1A1GAACCR2SPHK2SPHK1 | |
| SCHEMBL4338699 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4EGAAHPGDCNR1 | |
| SCHEMBL13612259 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4EGAAHPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | ALDH1A1 1459/4885KDM4E 3010/4885SIGMAR1 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.